Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes (Q34956921)

5 August 2017

title

Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes (English)

1 reference

5 August 2017

0 references

Abraham Weizman

1 reference

5 August 2017

Shmuel Davidson

1 reference

5 August 2017

Diana Prokonov

1 reference

5 August 2017

Michal Taler

1 reference

5 August 2017

Rachel Maayan

1 reference

5 August 2017

Daniella Harell

1 reference

5 August 2017

Irit Gil-Ad

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

5 August 2017

page(s)

236-241

1 reference

Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Perinatal outcome following third trimester exposure to paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Platelet serotonin in newborns and infants: ontogeny, heritability, and effect of in utero exposure to selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Outcomes of prenatal antidepressant exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Neonate characteristics after maternal use of antidepressants in late pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Risks associated with selective serotonin reuptake inhibitors in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Decreased growth during therapy with selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Role of neurotransmitters and neuropeptides in the regulation of the adrenal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Chronic maternal fluoxetine infusion in pregnant sheep: effects on the maternal and fetal hypothalamic-pituitary-adrenal axes

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Endocrine mechanisms of intrauterine programming

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Glucocorticoids stimulate the expression of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human placental trophoblast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Fetal programming of the hypothalamic-pituitary-adrenal (HPA) axis: low birth weight and central HPA regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Effect of maternal fluoxetine administration on uterine blood flow, fetal blood gas status, and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Serotonin regulates osteoclast differentiation through its transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Selective serotonin reuptake inhibitors and neuroendocrine function

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Glucocorticoid programming of the fetus; adult phenotypes and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

IGF-I and IGF-binding protein-1 are related to cortisol in human cord blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

Modulation of neurotransmitter systems by dehydroepiandrosterone and dehydroepiandrosterone sulfate: mechanism of action and relevance to psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318193594A

10.1203/PDR.0B013E318193594A

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

5 August 2017

1002717881

0 references

1 reference